临床活动期系统性红斑狼疮患者低疾病活动度与缓解的达成率、决定因素及结局
在多国前瞻性队列中,1,991例临床活动但未达LLDAS或DORIS的SLE患者随访中位2.5年,70.9%和55.6%分别达成LLDAS和DORIS;达成后47.0%和47.5%发生 flare,24个月内9.5%和7.9%出现器官损伤累积。长时间维持目标状态与较低flare风险相关,但初始达标后flare和损伤仍常见,需进一步研究维持策略。
要点
- 临床活动期SLE患者中70.9%达成LLDAS、55.6%达成DORIS。
- 肾炎和低补体与达标时间延长相关,抗疟药和免疫抑制剂与达标时间缩短相关。
- 首次达标后flare和器官损伤仍频繁发生,需进一步研究维持目标的策略。
核心结论
- 在临床活动期SLE患者中,常规诊疗条件下达成LLDAS和DORIS的比例不理想,较长时间维持这些目标状态与flare风险降低显著相关,但初始达标后flare和器官损伤累积仍频繁发生,需进一步研究以指导维持目标的策略。
研究设计与样本
- 多国前瞻性队列观察,纳入1,991例临床有疾病活动但未达LLDAS或DORIS的SLE患者(93.2%为女性),中位(四分位距)观察2.5(0.7-4.5)年。
主要发现
- 70.9%的患者达成LLDAS,55.6%达成DORIS。
- 肾炎和低补体与达成LLDAS时间较长相关,抗疟药和免疫抑制剂使用与达成LLDAS时间较短相关。
- 首次达成LLDAS后47.0%的患者发生flare,首次达成DORIS后47.5%的患者发生flare。
- 首次达成LLDAS后24个月内9.5%的患者出现器官损伤累积,首次达成DORIS后24个月内7.9%的患者出现器官损伤累积。
- 较长的累计达标时间与抗疟药使用与flare和器官损伤累积时间较长相关,糖皮质激素和免疫抑制剂剂量减少与flare时间较短相关,免疫抑制剂减少也与器官损伤累积时间较短相关。
局限性
- 原文结论指出需进一步研究以指导维持这些目标的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment. METHODS: Patients in a multinational cohort with SLE who had clinical disease activity but were not in LLDAS or DORIS were observed prospectively. RESULTS: A total of 1,991 patients (93.2% female) were observed for a median (interquartile range) of 2.5 (0.7-4.5) years, with 70.9% and 55.6% achieving LLDAS and DORIS, respectively. Nephritis and low complements were associated with a longer time, and antimalarial and immunosuppressant use were associated with a shorter time to LLDAS attainment. After the first LLDAS and DORIS attainment, 47.0% and 47.5% of the patients experienced flare(s), respectively, and 9.5% and 7.9 % of patients accrued organ damage within 24 months, respectively. Longer cumulative time at target and antimalarial use was associated with a longer time to flare and damage accrual, whereas dose reduction in glucocorticoids and immunosuppressants was associated with a shorter time to flare. Reduction in immunosuppressants also correlated with a shorter time to damage accrual. CONCLUSION: In patients with SLE with clinical disease activity, the proportion attaining LLDAS and DORIS under usual care conditions is suboptimal. Longer maintenance of these states is significantly associated with reduced risk of flare. Because flares and damage accrual still occur frequently following initial target attainment, further research is needed to inform strategies for maintaining these targets.
引用
- Hao Y, Hansen D, Kandane-Rathnayake R, et al. Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active. Arthritis Care Res (Hoboken). 2025. PMID: 40955714. doi:10.1002/acr.25640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。